February 4, 2013
The Federal Association of German Pharmacists (BVDA)
today presented its "Innovation Award 2013" to FLEXISEQ®, an innovative new treatment for pain and stiffness associated with osteoarthritis (OA).
The BVDA president, and pharmacist Thomas Hieble, explained;
"The jury awarded the prize to FLEXISEQ® in recognition of the application of its innovative Sequessome Technology® to deliver symptom relief to sufferers of OA. The technology incorporates highly flexible phospholipid vesicles which can penetrate the skin and into the affected joint below. Once inside the joint, they accumulate on the surface of the cartilage to lubricate it. The result: pain relief and increased joint mobility - achieved conveniently and without the risk of the well recognised, systemic side effects associated with drugs typically used for the treatment of OA."
In their latest editions, various renowned medical journals such as "Ärzte Zeitung" and the "Zeitschrift für Rheumatologie" reported on this medical advance.
FLEXISEQ has an innovative mode of action due to its use of Sequessome Technology and its convenient gel formulation enables patients to self administer FLEXISEQ topically to the affected joint. The Sequessome™ vesicles contained within are proven to enter the synovial joint after application and increase phospholipid levels in the synovial fluid where they are known to be depleted in joints affected by OA. This physical, mode of action reduces the pain, (in phase III clinical trials, as effectively as the frequently prescribed oral drug medicine - celecoxib) and also improves joint mobility, thereby giving easier movement to patients.
Hundreds of millions of people worldwide suffer from OA, a chronic joint disease which makes the lives of those affected permanently more difficult. According to the Robert Koch Institute, the likelihood of contracting OA increases dramatically with age.